Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Comments

Loading...

Innovent Biologics Stock News

IVBXFOTCPK

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$7.39

0.314.45%

At close: -

$5.12

-2.27-30.77%

After Hours: May 21, 12:15 AM EDT

Innovent Biologics (IVBXF) Forecast

News

Earnings Innovent Biologics (IVBXF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest Innovent Biologics Stock News | OTC:IVBXF | Benzinga

Get the latest news on Innovent Biologics stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Innovent Biologics performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, August 04, 2022

Sanofi, Innovent Biologics Collaborate On Cancer Treatments In China
Vandana Singh

Thursday, April 14, 2022

The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
Vandana Singh

Wednesday, April 06, 2022

The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy
Shanthi Rexaline

Thursday, March 24, 2022

FDA Rejects Lilly's Sintilimab/Chemo Combo Therapy In First-Line Lung Cancer Setting
Vandana Singh

Friday, February 11, 2022

FDA AdComm Votes Against Lilly's Lung Cancer Drug, Sintilimab
Vandana Singh

Tuesday, September 28, 2021

Innovent Biologics, UNION therapeutics Ink Licensing Pact For Inflammatory Dermatology Candidate
Vandana Singh

Friday, August 27, 2021

Innovent Biologics, Bolt Join Forces To Develop Anti-Cancer Candidates
Vandana Singh

Monday, August 16, 2021

Innovent's Sintilimab/Chemo Regime Shows Overall Survival Benefit In Gastric Cancer
Vandana Singh

Friday, August 06, 2021

Innovent - Eli Lilly's Sintilimab Combo Shows Sustained Survival Benefit In Lung Cancer Patients
Vandana Singh

Friday, July 09, 2021

Innovent Biologics - Incyte's Pemigatinib Application Under Review In China For Bile Duct Cancer
Vandana Singh

Thursday, June 03, 2021

Eli Lilly-Innovent Biologics Score Expanded Use Approval of Tyvyt n Lung Cancer Patients In China
Vandana Singh

Tuesday, May 18, 2021

Lilly-Innovent's Sintilimab Plus Chemo Application For Lung Cancer Under Review With FDA
Vandana Singh

Wednesday, February 03, 2021

Innovent and Lilly Jointly Announced the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Pemetrexed and Platinum Chemotherapy as First-Line Therapy for Nonsquamous Non-Small Cell Lung Cancer
Charles Gross
Eli Lilly, Innovent Biologics' Sintilimab Injection Receives China Approval For A Type Of Lung Cancer
Vandana Singh

Connect With Us

About Benzinga

About Us
Careers
Advertise
Contact Us

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Benzinga Pro Trading Platform
Options Trading Strategies and News
Stock Market Trading Ideas and Analysis
Technical Analysis Charts and Indicators
Fundamental Analysis and Valuation
Day Trading Guides and Strategies
Live Investors Events
Pre market Stock Analysis and News
Cryptocurrency Market Analysis and News

Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved